HCPCS Code J1306: Inclisiran 1 mg billing guide

Key Takeaways

HCPCS Code J1306 describes Injection, inclisiran, 1 mg (Leqvio): bill 284 units per standard 284 mg dose.

J1306 is a medical benefit drug requiring prior authorization from most commercial payers and Medicare Advantage plans.

Paired ICD-10-CM codes include E78.00, E78.011, E78.010, E78.1, E78.2, E78.41, E78.49, and E75.5 for lipid disorder diagnoses.

Pabau’s claims management software helps practices track J-code claim submissions, modifier usage, and prior authorization status in one workflow.

HCPCS Code J1306 is a billable code for Injection, inclisiran, 1 mg (Leqvio), a twice-yearly PCSK9 inhibitor for adults with high LDL-C who have not responded to statins. One unit equals 1 mg, so the standard 284 mg dose is billed as 284 units.

Inclisiran follows a buy-and-bill pathway with documentation and submission requirements that differ from most injectable drugs. This guide covers the official descriptor, unit count, qualifying ICD-10-CM codes, modifier rules, prior authorization expectations, the NDC crosswalk, Medicare reimbursement context, and a step-by-step claim submission overview.

HCPCS Code J1306 code descriptor and drug overview

HCPCS Code J1306 is maintained by the Centers for Medicare and Medicaid Services (CMS) under the HCPCS Level II J-code category for drugs administered by injection. The official descriptor is: Injection, inclisiran, 1 mg. One billable unit equals 1 mg, so the standard 284 mg Leqvio dose requires 284 units on the claim line.

Inclisiran (brand name Leqvio, manufactured by Novartis Pharmaceuticals Corporation) is a small interfering RNA (siRNA) therapy that reduces LDL cholesterol by silencing PCSK9 production in the liver.

It is FDA-approved for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), as an adjunct to diet and maximally tolerated statin therapy. Unlike monoclonal antibody PCSK9 inhibitors, inclisiran is dosed only twice yearly after the initial loading sequence, making accurate per-encounter billing critical.

J1306 is valid for the 2026 billing year. It falls under the AAPC’s HCPCS Level II code lookup in the J1000-J8999 drugs-administered-other-than-oral-method range. Like other per-milligram injectable drug codes such as HCPCS Code J9299 (nivolumab), one unit equals 1 mg, so the unit count must match the milligrams administered. Practices using claims management software with built-in HCPCS support can validate J1306 at the point of charge entry to prevent downstream denials.

Dosing schedule and billing frequency

The inclisiran dosing protocol is: initial dose (284 mg), a second dose at 3 months, then maintenance doses every 6 months thereafter. Each encounter generates a separate J1306 claim for 284 units. There is no partial-dose scenario in routine practice; the full 284 mg prefilled syringe is used each time.

Billing units for J1306: calculating the correct unit count

Because J1306 defines one unit as 1 mg, billing the 284 mg dose means submitting 284 units on a single claim line. This is the single most common cause of J1306 underpayment: billers who enter “1 unit” receive reimbursement for only 1 mg instead of the full dose value.

Practices should hard-code 284 as the default unit value for J1306 in their practice management system’s charge entry templates to eliminate manual calculation errors at the point of service.

Covered ICD-10-CM diagnosis codes for J1306 billing

Payers use ICD-10-CM diagnosis codes to confirm medical necessity for inclisiran, and J1306 requires at least one covered diagnosis on the claim. The lipid disorder codes accepted by major payers include the following.

ICD-10-CM code lists are payer-specific and subject to annual updates. UnitedHealthcare and Carelonrx both publish inclisiran clinical criteria documents that specify accepted codes by plan year. Practices managing patients with metabolic health conditions should verify the accepted code list against each payer’s current medical policy before submitting a J1306 claim.

ASCVD as a concurrent diagnosis

Many payers also require documented atherosclerotic cardiovascular disease (ASCVD) or evidence of statin intolerance as a prerequisite for inclisiran coverage. Record the specific ASCVD ICD-10 code (for example, I25.10 for coronary artery disease) alongside the lipid disorder code. Some policies also recognize diabetes, such as ICD-10 Code E11.9, as a qualifying cardiovascular risk factor. Omitting a required diagnosis when the payer’s policy calls for it is a predictable denial trigger.

Modifiers used with HCPCS Code J1306

Two CMS drug waste modifiers can apply to J1306. Under CMS policy effective July 1, 2023, Part B claims for drugs supplied in single-dose containers must carry either a JW or a JZ modifier. Confirm whether inclisiran appears on your MAC’s current single-dose-container list before applying these modifiers, as applicability can vary.

• JW modifier (drug waste): Append JW when a portion of the single-dose vial or prefilled syringe is discarded unused. Report the administered units on the primary J1306 line and the wasted units on a second J1306 line with JW. Because Leqvio is supplied as a single-dose 284 mg/1.5 mL prefilled syringe, waste is unlikely in standard practice, but document any discarded volume.
• JZ modifier (no drug waste): Append JZ when the entire contents of the single-dose container are administered with no waste. Where the requirement applies, JZ is the correct modifier for a full 284 mg syringe with no discarded volume.

State Medicaid programs may have separate modifier requirements. Confirm the applicable rule with your Medicaid Administrative Contractor (MAC) or payer portal before submission. Practices using EHR integration workflows can flag drug waste documentation automatically at the point of administration, reducing the manual reconciliation step at billing.

Place of service codes

J1306 is most commonly administered in physician office (POS 11) or outpatient hospital (POS 22) settings. Reimbursement rates differ between settings under Medicare: physician office rates apply the ASP-based formula, while hospital outpatient rates follow OPPS. Submit the POS code that accurately reflects where the injection occurred. Submitting POS 11 for a hospital-based encounter is a common audit trigger for Part B drug claims.

Streamline your J-code billing workflow

Pabau's claims management tools help practices track prior authorization status, attach the correct modifiers, and submit J-code claims without manual workarounds. See how it works for metabolic and cardiology practices.

Book a demo

Prior authorization requirements for J1306

Inclisiran requires prior authorization (PA) under the medical benefit for most commercial payers and Medicare Advantage plans. MDwise, Moda Health, and UnitedHealthcare all classify J1306 as medical benefit only with PA required. Submitting without an approved PA is the top cause of denial for this drug.

Standard PA criteria across payers typically include:

• Confirmed diagnosis of primary hyperlipidemia or HeFH or HoFH with supporting ICD-10 code
• Documented LDL-C level above payer-specified threshold (commonly 70 mg/dL or 100 mg/dL depending on cardiovascular risk category)
• Evidence of maximally tolerated statin therapy or documented statin intolerance
• Prescribing clinician is a cardiologist, lipidologist, or relevant specialist (some plans require specialist involvement)
• Previous trial of other LDL-lowering therapies (PCSK9 inhibitors or ezetimibe, plan-specific)

Maintaining thorough PA documentation in secure patient records is essential for both initial approvals and denial appeals. PA approvals typically cover a 12-month period and require renewal. Some plans authorize the initial and 3-month doses under a single PA; others require a new request for each maintenance dose. Verify this with the specific plan before scheduling the maintenance injection.

PA denial appeal workflow

When a PA is denied, request a peer-to-peer review within the payer’s appeal window (typically 30-60 days from denial). Include LDL-C lab results, prior lipid-lowering therapy records, and the clinical rationale for inclisiran over alternatives. Specific references to published ORION trial data and FDA-approved labeling strengthen the appeal. Document the appeal in the patient chart with dates, contact names, and outcome. Practices using standardized medical documentation workflows can pull these records quickly during the appeal timeline.

NDC crosswalk and Medicare reimbursement for J1306

The National Drug Code (NDC) for Leqvio 284 mg/1.5 mL single-dose prefilled syringe is 00078-1000-xx (the final two digits vary by lot). NDC reporting on Part B drug claims is mandatory under CMS policy. Format the NDC in 5-4-2 segments with leading zeros: for example, 00078-1000-60. Report the NDC quantity as 1.5 (mL) with unit qualifier ML for a full 1.5 mL syringe.

Medicare Part B reimburses most covered drugs at ASP plus 6% for physician office administration. For J1306, reimbursement is tied to CMS quarterly ASP updates published on the CMS Physician Fee Schedule lookup. Because ASP changes each quarter, practices should verify the current rate before estimating patient cost-sharing or projecting practice revenue from inclisiran administration.

Commercial payer reimbursement rates vary and are set by individual payer contracts rather than a public fee schedule. Because these amounts are payer-negotiated and date-sensitive, confirm the current contracted rate for J1306 with each payer before financial counseling or revenue projection.

Buy-and-bill vs. specialty pharmacy pathway

Under buy-and-bill, the practice purchases Leqvio directly from a distributor, administers it, and bills J1306 to the medical benefit. Under the specialty pharmacy pathway, the payer routes the drug through a contracted pharmacy that ships to the practice or patient. Many commercial payers default inclisiran to specialty pharmacy, which affects how (and whether) J1306 is billed separately.

Verify the dispensing pathway before purchasing inventory. If the payer requires specialty pharmacy fulfillment but the practice purchased and administered the drug under buy-and-bill, the claim may be denied as a benefit carve-out. Using prescription management software that flags dispensing pathway requirements by payer reduces this exposure.

Documentation requirements for J1306 claim submission

CMS and commercial payers expect specific documentation to support each J1306 encounter. Meeting these requirements upfront prevents retrospective denial on audit. Apply HIPAA-compliant documentation practices for all records associated with inclisiran administration.

• Current LDL-C lab result: Document the most recent LDL-C value with date of test. Payers compare this against their coverage threshold.
• Diagnosis code justification: The clinical note must support the ICD-10-CM code(s) submitted. “Hyperlipidemia” without specificity codes inconsistently with E78.011 (HeFH), for example.
• Statin therapy history: Record the statin(s) tried, doses, duration, and reason for discontinuation or non-escalation.
• Injection administration note: Date, time, drug name, NDC, lot number, dose in mg, route (subcutaneous), anatomical site (upper arm, abdomen, or thigh), and administering clinician.
• JW or JZ modifier documentation: If JW is used, document the wasted volume in the administration note. If JZ, confirm complete administration of the vial.
• PA approval reference: Record the payer’s PA approval number and effective dates in the encounter note or billing record.

Practices using digital intake and clinical forms can template these documentation fields into the inclisiran encounter workflow, ensuring nothing is omitted before the charge is posted. A structured administration note also satisfies audit requirements under primary care compliance checklists for injectable drug billing.

How to submit J1306 claims: CMS-1500 and UB-04

J1306 applies to both professional and institutional claim formats, but submission details differ by setting. For professional claims on the CMS-1500 form, use these field entries.

For hospital outpatient (UB-04) submissions, report J1306 in Form Locator 44 (Revenue Code 0636 for pharmacy) with the HCPCS code, units, and NDC in the appropriate revenue lines. Attach the PA approval number in the remarks field when required. The same claim discipline applies to other injectable drug codes, including unclassified ones such as HCPCS Code J3590. Verify submission requirements with your Medicare Administrative Contractor for the most current formatting rules, since NDC reporting format requirements can vary by MAC.

Conclusion

Inclisiran’s twice-yearly dosing schedule makes each encounter high-value, which also makes billing errors disproportionately costly. Getting the unit count right (284), pairing the correct ICD-10-CM lipid disorder code, applying the JZ or JW modifier, and securing PA before the first dose are the four checkpoints that determine whether a J1306 claim pays cleanly or cycles through denials.

Pabau’s claims management software gives cardiology, lipidology, and metabolic health practices a structured workflow to track PA status, apply modifiers, attach NDC data, and monitor claim outcomes across a J1306 patient panel. To see how Pabau handles injectable drug billing for specialty practices, book a demo.

Continue your research

Need to manage injectable drug claims across multiple payers? Best medical practice management software covers the key features that simplify multi-payer J-code billing.

Running a metabolic or weight management practice that administers injectables? Weight loss and metabolic clinic software explains how Pabau supports GLP-1 and lipid-management workflows.

Looking to reduce documentation burden at the point of administration? Medical dictation tools reviews how AI-assisted notes capture injection administration details efficiently.

Frequently asked questions